New targeted drug hopes to shrink Hard-to-Treat cancers
NCT ID NCT06257264
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 34 times
Summary
This early-phase study tests a new drug, BG-68501, in about 100 adults with advanced solid tumors (like breast, ovarian, or lung cancer) that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors when used alone or with other medicines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105-2108, United States
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
Cancer Research South Australia
Adelaide, South Australia, SA 5000, Australia
-
Florida Cancer Specialists and Research Institute
Lake Mary, Florida, 32746-2115, United States
-
Genesiscare North Shore
St Leonards, New South Wales, NSW 2065, Australia
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Hoag Memorial Presbyterian
Newport Beach, California, 92663-4162, United States
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
Nepean Hospital
Kingswood, New South Wales, NSW 2747, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, QLD 4102, Australia
-
Rambam Health Care Center
Haifa, 3109601, Israel
-
Saint Vincents Hospital Sydney
Darlinghurst, New South Wales, NSW 2010, Australia
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Shengjing Hospital of China Medical Universityhuaxiang Branch
Shenyang, Liaoning, 110022, China
-
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, 510245, China
-
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, 710061, China
-
The Institute of Oncology, Arensia Exploratory Medicine
Chisinau, 2025, Moldova
-
Titan Health Partners Llc Dba Astera Cancer Care
East Brunswick, New Jersey, 08816-4096, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110-1010, United States
Conditions
Explore the condition pages connected to this study.